Brief: ARCA Says COVID-19 Data And Safety Monitoring Committee Recommends Continuing Phase 2B Clinical Trial
28/10/2021 23:08
Oct 28 (Reuters) - ARCA Biopharma Inc ABIO.O :
* ASPEN-COVID-19 DATA AND SAFETY MONITORING COMMITTEE
RECOMMENDS
CONTINUING PHASE 2B CLINICAL TRIAL TO COMPLETION BASED ON
INTERIM ANALYSIS OF EFFICACY AND SAFETY DATA
* ARCA BIOPHARMA INC - ENROLLMENT COMPLETION ANTICIPATED BY
YEAR
END 2021
* ARCA BIOPHARMA INC - TOPLINE DATA ANTICIPATED IN Q1 OF
2022
Source text for Eikon: ID:nGNX8yWymb
Further company coverage: ABIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oruka Therapeutics
See all newsOruka falls after reporting mid-stage data for psoriasis drug
Brief: Oruka Therapeutics Announces Positive Week 28 Data For Orka-001 From The Ongoing Everlast-A Trial Showing Deepening Of Responses Without Additional Dosing
Brief: Oruka Therapeutics Appoints Todd Edwards As Chief Commercial Officer
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Oruka Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary